The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma. - Wikidata - awgldk - TriplyDB

The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.

The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.

http://www.wikidata.org/entity/Q34312854

about

Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up Recent advances in multidisciplinary management of hepatocellular carcinoma Combination treatment including targeted therapy for advanced hepatocellular carcinoma Minimally invasive image-guided therapies for hepatocellular carcinoma Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma.Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature.Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma.Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.Intermediate hepatocellular carcinoma: How to choose the best treatment modality?Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review.Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis.Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment.Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma.Comparing the long-term efficacy of standard and combined minimally invasive procedures for unresectable HCC: a mixed treatment comparison Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC).Treatment of hepatocellular carcinoma: a systematic review.Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety.Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.Transarterial chemoembolization and sorafenib in hepatocellular carcinoma.Interventional Oncology in Hepatocellular Carcinoma: Progress Through Innovation.CD147 is increased in HCC cells under starvation and reduces cell death through upregulating p-mTOR in vitro.Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma.Preparation and structure of drug-carrying biodegradable microspheres designed for transarterial chemoembolization therapy.Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma.Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma.Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma.Dendrimer-doxorubicin conjugates exhibit improved anticancer activity and reduce doxorubicin-induced cardiotoxicity in a murine hepatocellular carcinoma model.Transcatheter hepatic arterial chemoembolization and sorafenib for hepatocellular carcinoma: a meta-analysis of randomized, double-blind controlled trials.Puncture injection of para-toluenesulfonamide combined with chemoembolization for advanced hepatocellular carcinoma.TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial.Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma.Anti-tumor Effects of Sorafenib Administered at Different Time Points in Combination with Transarterial Embolization in a Rabbit VX2 Liver Tumor Model.Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib.Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study.

P2860

Q26851033-0A67E4E9-3C93-40A6-9246-656463575DE7 Q26863748-60B53700-04C0-4204-B0D7-93C82E3C747B Q28077738-C2B07F89-4D22-4300-8DFC-0F1497D5D77F Q28079027-4B3CF50B-5734-401D-9A9E-E9F13B094A1C Q33778970-8FF8F1CA-04EB-4D95-A92C-98BD6A875843 Q34292971-4022B560-F303-4AE2-BD63-E414E6C42259 Q34702094-70FF8A79-68CD-491D-93D4-2CA275EA6AD4 Q34770140-76B02A51-8178-40BE-B070-CA65A0C991BB Q34991643-6186D1FC-6C1A-4945-A114-DDB55FFB70F7 Q35025403-AD288F5F-8176-4292-B7A6-7C0301E5212F Q35219226-6CE54920-0E07-4770-B261-8646A44CD897 Q35626764-54B8EF54-435C-47E4-81D8-ED1D60C6A81D Q35917459-F0705A39-A1AE-4202-A880-722B247ED874 Q36210228-BF76D914-C68A-4CAA-8BD4-B4C11DC34258 Q37103489-CAEC4C3B-C149-4793-9676-E775AE79BD26 Q37581359-FCFDDD0C-06D8-4A50-B579-133C283C6B15 Q37687559-A184E0DB-C89E-4BBA-9876-3FA74F661BE3 Q37716505-4C367C17-950C-4144-9784-D7C946B2FF2C Q38075142-59EAF515-663B-4E5F-A809-E13FDB0486F7 Q38155508-6827FE5C-3FE6-4FD6-AC98-EA88C0C9C019 Q38160838-132FAB41-3AD8-465C-AF21-2F1EBD111E55 Q38197831-626E2847-76D5-4B09-AD62-DB0C164E956D Q38207487-B84B7283-DE7D-4F7A-94B5-AEEB71EF1FDE Q38213650-6057C743-1574-4B0D-B91D-59F84D64D921 Q38792625-EEFDF942-206F-4179-A91D-258C0737F7E2 Q38825534-1E55EEB5-7B78-490D-9FB1-DF01E693175C Q38830206-5FE67DBA-5832-4C9E-90CF-D84AA411D057 Q38937729-6C3AEA35-B0B8-458B-AD2B-C982598E4EA2 Q39375746-5648070C-3DB4-48EF-B9EF-D8D9CD958987 Q40137729-AAA53D66-F559-4C77-B4A7-7659F297D5A9 Q40846805-E7EFFE43-FBD8-418A-B552-CDD8463BDCC8 Q41493235-2C95F1BB-2BFA-4893-B650-68DA02E823B9 Q41708999-8D6604C7-FA16-4639-8AC1-C8FAF6D1FE6D Q42041675-E7207B67-2730-448D-AD40-9422E7F1D652 Q42199684-3F942A3F-B19D-43C5-9CCB-35EAD13E4BF1 Q47165734-78CF6E2C-89CB-4AE5-826C-01A1A3B486F3 Q48309588-4D930404-0B66-407E-9E97-E25D44FAE450 Q48722303-0299F828-494B-43B5-AFF7-3314C6A5B2DB Q49330012-7C0BF0C0-D781-4CFF-A58D-5E7681E5AD75 Q53818396-4EF286EE-3F88-4061-845B-E0B8CDD2B298

P2860

The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.

http://www.wikidata.org/entity/Q34312854

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.

@ast

The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.

@en

The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.

@nl

type

label

The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.

@ast

The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.

@en

The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.

@nl

prefLabel

The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.

@ast

The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.

@en

The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.

@nl

P1433

Q34312854-86CAE7E4-8CA2-4479-92E7-407810D28DF2

P1476

Q34312854-E60E8C74-D37C-4558-93DE-6A40094C5B93

P2093

Q34312854-1C5D60DC-626F-450A-9078-5F991EDCD121

Q34312854-2D1D0CE1-B76D-48F2-A42B-AA6B4AF306F8

Q34312854-37DDC223-CF52-4F37-9DA7-39AE522998ED

Q34312854-39FDBF2C-B6DE-496C-AAFE-7E8D92865924

Q34312854-3D1C2669-03D1-494B-88D1-8965DB20EC12

Q34312854-7905C832-4E72-41A7-BABA-C19D3FB30BC3

Q34312854-793D6ECF-83E5-4DDD-8286-81408593888C

Q34312854-837D41F1-6ECE-4CB7-86B7-5315BEA4DCF7

Q34312854-BCF5336D-69E6-4B38-AEA8-B9BB1D77884E

Q34312854-D11D0C1E-5F9B-43DB-B299-D5F63B513BA3

P2860

Q34312854-2C9EFC6A-5FFE-406A-8F25-098243D16948

Q34312854-30940258-411A-4AE0-B28A-FF4A56F163D3

Q34312854-345E63BF-9DD4-41A2-B7AE-A1481A300239

Q34312854-3AFFF634-C086-4E95-87F0-26848B264B60

Q34312854-4117DE1B-DD17-4A53-B584-2F7FA00D80E6

Q34312854-4247427E-1B05-487A-B89D-F3F3BDFDEE75

Q34312854-48C2DAE6-387F-4242-A3E1-B7D0AF6B1341

Q34312854-64B19F47-8523-467C-B183-E4CB70684113

Q34312854-6DBDEDC6-0222-47DC-A5C2-A9D6461048AE

Q34312854-6F05B9BC-E003-4E4D-B7E7-EBAEE437AB80

P2888

Q34312854-92E20C0F-FC02-4354-B237-EB47402774FB

P304

Q34312854-F65570DF-0F94-4BFE-A3F9-AF75B41C84A2

P31

Q34312854-CAC26C5E-1B2A-466D-AAC6-9B3CE96A65D4

P356

Q34312854-816E8DBA-5B07-48FB-9B17-E22BDB1CEA94

P407

Q34312854-0149A3AF-4443-403C-A413-4EEC9B24F492

P478

Q34312854-990772A3-3EAC-4420-8A2A-BCAEC978804C

P577

Q34312854-E921F8C5-13C2-4CAF-9ECD-85BB7E4A9FF4

P5875

Q34312854-7D8FE1C2-B5EE-48E8-8B8B-32CEADB74796

P6179

Q34312854-20A6514D-309F-4189-A6E1-2AD089C4E642

P698

Q34312854-17B88E39-BB53-462D-8638-CF63284A33C0

P932

Q34312854-C742FC75-75DE-4393-A183-A8210BF81422

P356

1471-2407-12-263

P1433

P1476

The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.

@en

P2093

Cheng-Shi Chen

http://www.w3.org/2001/XMLSchema#string

Gao-quan Gong

http://www.w3.org/2001/XMLSchema#string

Jian-Hua Wang

http://www.w3.org/2001/XMLSchema#string

Jian-jun Luo

http://www.w3.org/2001/XMLSchema#string

Jie-min Chen

http://www.w3.org/2001/XMLSchema#string

Lin-xiao Liu

http://www.w3.org/2001/XMLSchema#string

Qin-xin Liu

http://www.w3.org/2001/XMLSchema#string

Rong Liu

http://www.w3.org/2001/XMLSchema#string

Sheng Qian

http://www.w3.org/2001/XMLSchema#string

Xu-Dong Qu

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2002

Sorafenib in advanced hepatocellular carcinoma

Sorafenib: a review of its use in advanced hepatocellular carcinoma

Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Hepatocellular carcinoma

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

P2888

1471-2407-12-263

P304

263

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-12-263

http://www.w3.org/2001/XMLSchema#string

P407

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227855895

http://www.w3.org/2001/XMLSchema#string

P6179

1005203997

http://www.w3.org/2001/XMLSchema#string

P698

22721173

http://www.w3.org/2001/XMLSchema#string

P932

3411397

http://www.w3.org/2001/XMLSchema#string